Amisulpride for adults with refractory schizophrenia: a review of the clinical effectiveness and safety
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001025
English
Authors' recommendations:
Results from one non-randomized study suggest that the odds of remission, recovery or adequate quality of life with both amisulpride and clozapine were not statistically different from olanzapine. When just those patients in the study who remained on the same treatment for 36 months were considered, the odds of remission with amisulpride and clozapine was lower than olanzapine.
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/htis/june-2011/RC0276_Amisulpride_for_Adults_with_Refractory_Schizophrenia_Final.pdf
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antipsychotic Agents
- Schizophrenia
- Sulpiride
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.